Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 5 (1), 44-54
- https://doi.org/10.1038/ncponc0982
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission TomographyClinical Cancer Research, 2004
- Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.2004
- Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug developmentEuropean Journal of Clinical Pharmacology, 2003
- Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.2003
- Metabolic activation of temozolomide measured in vivo using positron emission tomography.2003
- Pharmacokinetics of Radiolabelled Anticancer Drugs for Positron Emission TomographyCurrent Pharmaceutical Design, 2003
- Noninvasive imaging of protein–protein interactions in living subjects by using reporter protein complementation and reconstitution strategiesProceedings of the National Academy of Sciences of the United States of America, 2002
- Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)European Journal Of Cancer, 2002